Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q3 FY25 results · Oct–Dec 2024
Neuland Laboratories reported revenue from operations of ₹398.03 crore (up 1.3% from Q3 FY24) and net profit of ₹101.59 crore (up 24.8% from Q3 FY24) for Q3 FY25 (Oct–Dec 2024), on a consolidated basis.
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 398.03 | 392.83 | +1.3% | 310.84 | +28.0% |
| Other income | 3.91 | 2.10 | +85.9% | 4.33 | −9.9% |
| Total income | 401.94 | 394.93 | +1.8% | 315.18 | +27.5% |
| Profit before tax | 127.76 | 104.48 | +22.3% | 49.42 | +158.5% |
| Net profit for the period | 101.59 | 81.39 | +24.8% | 32.84 | +209.3% |
| EPS, basic (₹) | 79.18 | 63.44 | +24.8% | 25.60 | +209.3% |
| Net margin (%) | 25.5 | 20.7 | 10.6 |
| Item | Q3 FY25 | Q3 FY24 | YoY | Q2 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 398.03 | 392.83 | +1.3% | 310.84 | +28.0% |
| Other income | 3.91 | 2.10 | +85.9% | 4.33 | −9.9% |
| Total income | 401.94 | 394.93 | +1.8% | 315.18 | +27.5% |
| Profit before tax | 127.54 | 103.78 | +22.9% | 48.54 | +162.8% |
| Net profit for the period | 101.39 | 80.70 | +25.6% | 31.96 | +217.3% |
| EPS, basic (₹) | 79.03 | 62.90 | +25.6% | 24.91 | +217.3% |
| Net margin (%) | 25.5 | 20.5 | 10.3 |
Consolidated
- Filed with BSE
- 10 Feb 2025, 17:17 IST
- Board meeting
- 10 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Feb 2025, 17:17 IST
- Board meeting
- 10 Feb 2025
- Period
- 01 Oct 2024 to 31 Dec 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE